NCT01715142 - Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 21, 2013

Primary Completion Date

September 21, 2015

Study Completion Date

April 30, 2017

Conditions

Pancreatic Adenocarcinoma ResectablePancreatic Adenocarcinoma Locally AdvancedPancreatic Adenocarcinoma Metastatic

Interventions

DRUG

Gemcitabine

Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)

DRUG

Abraxane

Administrated intravenously at a dose of 125 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)

Trial Locations (2)

1070

Erasme University Hospital (ULB), Brussels

2650

Antwerp University Hospital (UZA), Edegem